JinkoSolar Holding Co., Ltd. (JKS) Reaches $23.74 After 7.00% Up Move; Sage Therapeutics (SAGE) Shorts Raised By 4.6%

July 17, 2017 - By Peter Erickson

The stock of JinkoSolar Holding Co., Ltd. (NYSE:JKS) is a huge mover today! About 1.26M shares traded or 47.18% up from the average. JinkoSolar Holding Co., Ltd. (NYSE:JKS) has declined 11.42% since July 17, 2016 and is downtrending. It has underperformed by 28.12% the S&P500.The move comes after 5 months positive chart setup for the $804.52 million company. It was reported on Jul, 17 by Barchart.com. We have $25.40 PT which if reached, will make NYSE:JKS worth $56.32M more.

Sage Therapeutics Incorporated (NASDAQ:SAGE) had an increase of 4.6% in short interest. SAGE’s SI was 4.71M shares in July as released by FINRA. Its up 4.6% from 4.50 million shares previously. With 340,600 avg volume, 14 days are for Sage Therapeutics Incorporated (NASDAQ:SAGE)’s short sellers to cover SAGE’s short positions. The SI to Sage Therapeutics Incorporated’s float is 13.95%. About 147,203 shares traded. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 116.45% since July 17, 2016 and is uptrending. It has outperformed by 99.75% the S&P500.

Among 7 analysts covering JinkoSolar Holding Co. (NYSE:JKS), 4 have Buy rating, 2 Sell and 1 Hold. Therefore 57% are positive. JinkoSolar Holding Co. had 12 analyst reports since August 25, 2015 according to SRatingsIntel. Northland Capital initiated JinkoSolar Holding Co., Ltd. (NYSE:JKS) rating on Friday, December 18. Northland Capital has “Outperform” rating and $46 target. Roth Capital maintained the stock with “Buy” rating in Friday, November 20 report. The stock of JinkoSolar Holding Co., Ltd. (NYSE:JKS) has “Outperform” rating given on Monday, March 21 by Credit Suisse. The company was maintained on Friday, November 20 by TH Capital. The stock has “Hold” rating by Roth Capital on Monday, June 5. The stock of JinkoSolar Holding Co., Ltd. (NYSE:JKS) has “Neutral” rating given on Friday, August 5 by Roth Capital. Morgan Stanley downgraded the stock to “Underweight” rating in Friday, May 26 report. The rating was maintained by Roth Capital on Tuesday, August 25 with “Buy”. The stock of JinkoSolar Holding Co., Ltd. (NYSE:JKS) earned “Sell” rating by Citigroup on Friday, May 26.

Analysts await JinkoSolar Holding Co., Ltd. (NYSE:JKS) to report earnings on August, 24. They expect $0.69 EPS, down 62.90% or $1.17 from last year’s $1.86 per share. JKS’s profit will be $23.38M for 8.60 P/E if the $0.69 EPS becomes a reality. After $0.28 actual EPS reported by JinkoSolar Holding Co., Ltd. for the previous quarter, Wall Street now forecasts 146.43% EPS growth.

JinkoSolar Holding Co., Ltd. operates in the photovoltaic industry. The company has market cap of $804.52 million. The Firm has built a vertically integrated solar power product value chain, from recovering silicon materials to manufacturing solar modules and solar power generation. It has a 9.12 P/E ratio. The Company’s divisions include the manufacturing segment and the solar power projects segment.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $3.11 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: